Acute Renal Failure (ARF), Acute Tubular Necrosis
Conditions
Keywords
acute renal failure, acute tubular necrosis
Brief summary
Use of QRX-3 in hospitalized patients with pediatric and adult patients with acute tubular necrosis renal failure
Interventions
DRUGQRX-3
Combination of QRX-3 with standard therapy will be given to one arm in trial , another arm will receive placebo
Sponsors
Ebima Clifford Okundaye
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
added QRX-3 to standard regime
Eligibility
Sex/Gender
ALL
Age
10 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Hospitalized patients * presence of Acute renal failure * Nephrologist diagnosis of Acute tubular necrosis or fractional excretion of sodium of \>2% * willingness to participate
Exclusion criteria
High risk of bleeding Absence of hydronephrosis or obstructive uropathy Absence of baseline dialysis use single kidney status
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of change in creatinine glomerular filtration rate | 28 days | compare the outcome effect of added QRX-3 drug to placebo in addition to standard therapy on the rate of change from baseline of creatinine GFR in ATN patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| daily change in glomerular filtration rate in ml/min | 7 days | daily change in GFR by creatinine in mls/min |
| daily change in cystatin C level in mg/dl | 7 days | daily change in measured cystatin C level |
Countries
United States
Contacts
CONTACTEbima Okundaye, MD
Outcome results
None listed